uni-leipzig-open-access/json/jcm12062184

1 line
37 KiB
Text
Raw Normal View History

2024-01-25 13:46:53 +00:00
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T20:51:20Z","timestamp":1702068680153},"reference-count":97,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Despite an improvement in pharmacological therapies and mechanical reperfusion, the outcome of patients with acute myocardial infarction (AMI) is still suboptimal, especially in patients with cardiogenic shock (CS). The incidence of CS accounts for 3\u201315% of AMI cases, with mortality rates of 40% to 50%. In contrast to a large number of trials conducted in patients with AMI without CS, there is limited evidence-based scientific knowledge in the CS setting. Therefore, recommendations and actual treatments are often based on registry data. Similarly, knowledge of the available options in terms of temporary mechanical circulatory support (MCS) devices is not equally widespread, leading to an underutilisation or even overutilisation in different regions\/countries of these treatment options and nonuniformity in the management of CS. The aim of this article is to provide a critical overview of the available literature on the management of CS as a complication of AMI, summarising the most recent evidence on revascularisation strategies, pharmacological treatments and MCS use.<\/jats:p>","DOI":"10.3390\/jcm12062184","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T07:03:57Z","timestamp":1678691037000},"page":"2184","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Management of Cardiogenic Shock Complicating Acute Myocardial Infarction"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-8552-1272","authenticated-orcid":false,"given":"Leonardo","family":"De Luca","sequence":"first","affiliation":[{"name":"Department of Cardio-Thoracic and Vascular Medicine and Surgery, Division of Cardiology, A.O. San Camillo-Forlanini, 00152 Rome, Italy"},{"name":"Faculty of Medicine and Dentistry, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy"}]},{"given":"Raffaella","family":"Mistrulli","sequence":"additional","affiliation":[{"name":"Department of Cardio-Thoracic and Vascular Medicine and Surgery, Division of Cardiology, A.O. San Camillo-Forlanini, 00152 Rome, Italy"}]},{"given":"Riccardo","family":"Scirpa","sequence":"additional","affiliation":[{"name":"Department of Cardio-Thoracic and Vascular Medicine and Surgery, Division of Cardiology, A.O. San Camillo-Forlanini, 00152 Rome, Italy"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-0169-998X","authenticated-orcid":false,"given":"Holger","family":"Thiele","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Center Leipzig, University of Leipzig, 04289 Leipzig, Germany"}]},{"given":"Giuseppe","family":"De Luca","sequence":"additional","affiliation":[{"name":"Division of Cardiology, AOU \u201cPoliclinico G. Martino\u201d, Department of Clinical and Experimental Medicine, University of Messina, 98166 Messina, Italy"},{"name":"Division of Cardiology, IRCCS Hospital Galeazzi-Sant\u2019Ambrogio, 20161 Milan, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"ref_1","first-page":"e232","article-title":"Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association","volume":"136","author":"Katz","year":"2017","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jacc.2005.11.018","article-title":"Relationship between patient\u2019s risk profile and benefits in mortality from ad-junctive abciximab to mechanical revascularization for ST-segment elevation